Form 4: Fate Therapeutics Director Yuan Xu Sells Shares Under 10b5-1 Trading Plan

Director Yuan Xu of Fate Therapeutics sold 633 shares of common stock at a price of $4.23 per share on August 6, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On August 6, 2024, Yuan Xu, a director of Fate Therapeutics, sold 633 shares of common stock.
• The sale was executed at a price of $4.23 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on March 26, 2024.
• Following the transaction, Yuan Xu directly owns 8,669 shares of Fate Therapeutics.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a stock sale by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company insiders are a common occurrence and are often viewed in the context of the insider's overall holdings and the reasons for the sale (e.g., diversification, tax planning). The use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on immediate market conditions or inside information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the relatively small number of shares sold and the use of a 10b5-1 trading plan.

Key Dates